The Market Reports

Index

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Peptide and Oligonucleotide CDMO Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Peptide CDMO
1.2.3 Oligonucleotide CDMO
1.3 Market by Application
1.3.1 Global Peptide and Oligonucleotide CDMO Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Pharmaceutical and Biotechnology Companies
1.3.3 Research Institutes
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Peptide and Oligonucleotide CDMO Market Perspective (2018-2029)
2.2 Peptide and Oligonucleotide CDMO Growth Trends by Region
2.2.1 Global Peptide and Oligonucleotide CDMO Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Peptide and Oligonucleotide CDMO Historic Market Size by Region (2018-2023)
2.2.3 Peptide and Oligonucleotide CDMO Forecasted Market Size by Region (2024-2029)
2.3 Peptide and Oligonucleotide CDMO Market Dynamics
2.3.1 Peptide and Oligonucleotide CDMO Industry Trends
2.3.2 Peptide and Oligonucleotide CDMO Market Drivers
2.3.3 Peptide and Oligonucleotide CDMO Market Challenges
2.3.4 Peptide and Oligonucleotide CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Peptide and Oligonucleotide CDMO Players by Revenue
3.1.1 Global Top Peptide and Oligonucleotide CDMO Players by Revenue (2018-2023)
3.1.2 Global Peptide and Oligonucleotide CDMO Revenue Market Share by Players (2018-2023)
3.2 Global Peptide and Oligonucleotide CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Peptide and Oligonucleotide CDMO Revenue
3.4 Global Peptide and Oligonucleotide CDMO Market Concentration Ratio
3.4.1 Global Peptide and Oligonucleotide CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Peptide and Oligonucleotide CDMO Revenue in 2022
3.5 Peptide and Oligonucleotide CDMO Key Players Head office and Area Served
3.6 Key Players Peptide and Oligonucleotide CDMO Product Solution and Service
3.7 Date of Enter into Peptide and Oligonucleotide CDMO Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Peptide and Oligonucleotide CDMO Breakdown Data by Type
4.1 Global Peptide and Oligonucleotide CDMO Historic Market Size by Type (2018-2023)
4.2 Global Peptide and Oligonucleotide CDMO Forecasted Market Size by Type (2024-2029)
5 Peptide and Oligonucleotide CDMO Breakdown Data by Application
5.1 Global Peptide and Oligonucleotide CDMO Historic Market Size by Application (2018-2023)
5.2 Global Peptide and Oligonucleotide CDMO Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Peptide and Oligonucleotide CDMO Market Size (2018-2029)
6.2 North America Peptide and Oligonucleotide CDMO Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Peptide and Oligonucleotide CDMO Market Size by Country (2018-2023)
6.4 North America Peptide and Oligonucleotide CDMO Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Peptide and Oligonucleotide CDMO Market Size (2018-2029)
7.2 Europe Peptide and Oligonucleotide CDMO Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Peptide and Oligonucleotide CDMO Market Size by Country (2018-2023)
7.4 Europe Peptide and Oligonucleotide CDMO Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Peptide and Oligonucleotide CDMO Market Size (2018-2029)
8.2 Asia-Pacific Peptide and Oligonucleotide CDMO Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Peptide and Oligonucleotide CDMO Market Size by Region (2018-2023)
8.4 Asia-Pacific Peptide and Oligonucleotide CDMO Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Peptide and Oligonucleotide CDMO Market Size (2018-2029)
9.2 Latin America Peptide and Oligonucleotide CDMO Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Peptide and Oligonucleotide CDMO Market Size by Country (2018-2023)
9.4 Latin America Peptide and Oligonucleotide CDMO Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Peptide and Oligonucleotide CDMO Market Size (2018-2029)
10.2 Middle East & Africa Peptide and Oligonucleotide CDMO Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Country (2018-2023)
10.4 Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Lonza Group Ltd.
11.1.1 Lonza Group Ltd. Company Detail
11.1.2 Lonza Group Ltd. Business Overview
11.1.3 Lonza Group Ltd. Peptide and Oligonucleotide CDMO Introduction
11.1.4 Lonza Group Ltd. Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.1.5 Lonza Group Ltd. Recent Development
11.2 Thermo Fisher Scientific Inc.
11.2.1 Thermo Fisher Scientific Inc. Company Detail
11.2.2 Thermo Fisher Scientific Inc. Business Overview
11.2.3 Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Introduction
11.2.4 Thermo Fisher Scientific Inc. Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.2.5 Thermo Fisher Scientific Inc. Recent Development
11.3 Merck KGaA
11.3.1 Merck KGaA Company Detail
11.3.2 Merck KGaA Business Overview
11.3.3 Merck KGaA Peptide and Oligonucleotide CDMO Introduction
11.3.4 Merck KGaA Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.3.5 Merck KGaA Recent Development
11.4 Catalent, Inc.
11.4.1 Catalent, Inc. Company Detail
11.4.2 Catalent, Inc. Business Overview
11.4.3 Catalent, Inc. Peptide and Oligonucleotide CDMO Introduction
11.4.4 Catalent, Inc. Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.4.5 Catalent, Inc. Recent Development
11.5 Genscript Biotech Corporation
11.5.1 Genscript Biotech Corporation Company Detail
11.5.2 Genscript Biotech Corporation Business Overview
11.5.3 Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Introduction
11.5.4 Genscript Biotech Corporation Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.5.5 Genscript Biotech Corporation Recent Development
11.6 Polypeptide Group
11.6.1 Polypeptide Group Company Detail
11.6.2 Polypeptide Group Business Overview
11.6.3 Polypeptide Group Peptide and Oligonucleotide CDMO Introduction
11.6.4 Polypeptide Group Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.6.5 Polypeptide Group Recent Development
11.7 Bachem Holding AG
11.7.1 Bachem Holding AG Company Detail
11.7.2 Bachem Holding AG Business Overview
11.7.3 Bachem Holding AG Peptide and Oligonucleotide CDMO Introduction
11.7.4 Bachem Holding AG Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.7.5 Bachem Holding AG Recent Development
11.8 Wuxi Apptec Co., Ltd.
11.8.1 Wuxi Apptec Co., Ltd. Company Detail
11.8.2 Wuxi Apptec Co., Ltd. Business Overview
11.8.3 Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Introduction
11.8.4 Wuxi Apptec Co., Ltd. Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.8.5 Wuxi Apptec Co., Ltd. Recent Development
11.9 Ajinomoto Co., Inc.
11.9.1 Ajinomoto Co., Inc. Company Detail
11.9.2 Ajinomoto Co., Inc. Business Overview
11.9.3 Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Introduction
11.9.4 Ajinomoto Co., Inc. Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.9.5 Ajinomoto Co., Inc. Recent Development
11.10 Rentschler Biopharma SE
11.10.1 Rentschler Biopharma SE Company Detail
11.10.2 Rentschler Biopharma SE Business Overview
11.10.3 Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Introduction
11.10.4 Rentschler Biopharma SE Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.10.5 Rentschler Biopharma SE Recent Development
11.11 Corden Pharma GmbH
11.11.1 Corden Pharma GmbH Company Detail
11.11.2 Corden Pharma GmbH Business Overview
11.11.3 Corden Pharma GmbH Peptide and Oligonucleotide CDMO Introduction
11.11.4 Corden Pharma GmbH Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.11.5 Corden Pharma GmbH Recent Development
11.12 Senn Chemicals AG
11.12.1 Senn Chemicals AG Company Detail
11.12.2 Senn Chemicals AG Business Overview
11.12.3 Senn Chemicals AG Peptide and Oligonucleotide CDMO Introduction
11.12.4 Senn Chemicals AG Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.12.5 Senn Chemicals AG Recent Development
11.13 Almac Group
11.13.1 Almac Group Company Detail
11.13.2 Almac Group Business Overview
11.13.3 Almac Group Peptide and Oligonucleotide CDMO Introduction
11.13.4 Almac Group Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.13.5 Almac Group Recent Development
11.14 Lonza Custom Manufacturing
11.14.1 Lonza Custom Manufacturing Company Detail
11.14.2 Lonza Custom Manufacturing Business Overview
11.14.3 Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Introduction
11.14.4 Lonza Custom Manufacturing Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.14.5 Lonza Custom Manufacturing Recent Development
11.15 Creative Peptides
11.15.1 Creative Peptides Company Detail
11.15.2 Creative Peptides Business Overview
11.15.3 Creative Peptides Peptide and Oligonucleotide CDMO Introduction
11.15.4 Creative Peptides Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.15.5 Creative Peptides Recent Development
11.16 Swiss Customized Synthesis
11.16.1 Swiss Customized Synthesis Company Detail
11.16.2 Swiss Customized Synthesis Business Overview
11.16.3 Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Introduction
11.16.4 Swiss Customized Synthesis Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.16.5 Swiss Customized Synthesis Recent Development
11.17 Syngene
11.17.1 Syngene Company Detail
11.17.2 Syngene Business Overview
11.17.3 Syngene Peptide and Oligonucleotide CDMO Introduction
11.17.4 Syngene Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.17.5 Syngene Recent Development
11.18 Eurogentec
11.18.1 Eurogentec Company Detail
11.18.2 Eurogentec Business Overview
11.18.3 Eurogentec Peptide and Oligonucleotide CDMO Introduction
11.18.4 Eurogentec Revenue in Peptide and Oligonucleotide CDMO Business (2018-2023)
11.18.5 Eurogentec Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details